EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure‐Based Virtual Screening

Chun-Lin Yang, Yi-Wen Wu iD, Huang-Ju Tu iD, Yun-Hsuan Yeh, Tony Eight Lin iD, Tzu-Ying Sung, Mu-Chun Li iD, Shih-Chung Yen, Jui-Hua Hsieh iD, Ming-Chin Yu, Sen-Yung Hsieh iD, Hsing-Pang Hsieh iD und 2 weitere

Advanced Science · 2025-05 · 12 (19)

DOI: 10.1002/advs.202416323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 24.03.2025. Verfasst von Chun-Lin Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110301, Taiwan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Alternative Splicing, Protein Serine-Threonine Kinases, Protein-Tyrosine Kinases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, Intramural Research Program of the NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer is an aggressive malignancy with a poor prognosis and limited treatment options. Cdc‐like kinase 4 (CLK4), a kinase that regulates alternative splicing by phosphorylating spliceosome components, is implicated in aberrant splicing events driving pancreatic cancer progression. In this study, we established a computational model that integrates pharmacological interactions of CLK4 inhibitors with an improved hit rate. Through this model, we identified a novel CLK4 inhibitor, compound 150441, with a 50% inhibitory concentration (IC 50 ) value of 21.4 n m . Structure‐activity relationship analysis was performed to investigate key interactions and functional groups. Kinase profiling revealed that compound 150441 is selective for CLK4. Subsequent in vitro assays demonstrated that this inhibitor effectively suppressed cell growth and viability of pancreatic cancer cells. In addition, it inhibited the phosphorylation of key splicing factors, including serine‐ and arginine‐rich splicing factor (SRSF) 4 and SRSF6. Cell cycle analysis further indicated that the compound induced G2/M arrest, leading to apoptosis. RNA‐seq analysis revealed that the compound induced significant changes in alternative splicing and key biological pathways, including RNA processing, DNA replication, DNA damage, and mitosis. These findings suggest that compound 150441 has promising potential for further development as a novel pancreatic cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsAlternative SplicingProtein Serine-Threonine KinasesProtein-Tyrosine KinasesProtein Kinase InhibitorsHumansCell Line, TumorCell ProliferationApoptosisStructure-Activity RelationshipSerine-Arginine Splicing FactorsAntineoplastic Agents

Stichwörter der Autor:innen

CLK4alternative splicingkinase inhibitorpancreatic cancerstructure‐based virtual screening

Substanzen

Protein Serine-Threonine KinasesClk dual-specificity kinasesProtein-Tyrosine KinasesProtein Kinase InhibitorsSerine-Arginine Splicing FactorsAntineoplastic Agents

Autor:innen und Institutionen

  • Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110301, Taiwan.
  • Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, 110301, Taiwan.
  • Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County, 350401, Taiwan.
  • Biomedical Translation Research Center, Academia Sinica, Taipei, 115202, Taiwan.
  • Warshel Institute for Computational Biology, School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, 518172, China.
  • Division of Translational Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, NC, 27709, USA.

ORCID-Profile: Yi-Wen Wu, Huang-Ju Tu, Tony Eight Lin, Mu-Chun Li, Jui-Hua Hsieh, Sen-Yung Hsieh, Hsing-Pang Hsieh, Shiow-Lin Pan, Kai-Cheng Hsu

Förderung

  • National Science and Technology Council
  • Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan
  • Intramural Research Program of the NIH

Zitieren

APA

Yang, C. L., Wu, Y. W., Tu, H. J., Yeh, Y. H., Lin, T. E., Sung, T. Y., Li, M. C., Yen, S. C., Hsieh, J. H., Yu, M. C., Hsieh, S. Y., Hsieh, H. P., Pan, S. L., & Hsu, K. C. (2025). Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure‐Based Virtual Screening. Advanced Science, 12(19). https://doi.org/10.1002/advs.202416323

Vancouver

Yang CL, Wu YW, Tu HJ, Yeh YH, Lin TE, Sung TY, et al. Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure‐Based Virtual Screening. Advanced Science. 2025;12(19). doi:10.1002/advs.202416323

BibTeX
@article{Yang2025,
  author = {Yang, Chun-Lin and Wu, Yi-Wen and Tu, Huang-Ju and Yeh, Yun-Hsuan and Lin, Tony Eight and Sung, Tzu-Ying and Li, Mu-Chun and Yen, Shih-Chung and Hsieh, Jui-Hua and Yu, Ming-Chin and Hsieh, Sen-Yung and Hsieh, Hsing-Pang and Pan, Shiow-Lin and Hsu, Kai-Cheng},
  title = {Identification and Biological Evaluation of a Novel CLK4 Inhibitor Targeting Alternative Splicing in Pancreatic Cancer Using Structure‐Based Virtual Screening},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {19},
  doi = {10.1002/advs.202416323}
}
Kostenlos starten →